Tuesday, August 16, 2022
News
NEWS HOME
»
PRN INDIA
NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe
  SocialTwist Tell-a-Friend  
   

- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise

- Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe

- Obicetrapib is a next-generation oral, low-dose and once-daily CETP inhibitor for which promising safety and strong LDL-lowering efficacy has been observed in patients with dyslipidemia through Phase 2b

MIAMI and FLORENCE, Italy and NAARDEN, Netherlands, June 28, 2022 /PRNewswire/ -- NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international pharmaceutical company, today announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases. Obicetrapib is NewAmsterdam's next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor therapeutic candidate, for which a promising safety and efficacy profile as an LDL-lowering adjunct to maximally tolerated statin therapy in patients with dyslipidemia has been observed through Phase 2b trials. Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer's disease.

 

Menarini Industrie Farmaceutiche Riunite Logo

 

"We are delighted to enter into this agreement with Menarini," said Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma. "As we advance obicetrapib through late-stage clinical development, we believe now is the right time to begin laying the groundwork for our global product launch. Menarini is a leading pharmaceutical company with substantial cardiovascular expertise and the greatest share of voice among cardiologists, internists and general practitioners across major European markets, as well as strong relationships with key opinion leaders.   We believe they are the right partner to accelerate efforts to maximize the delivery of obicetrapib, upon approval, to the millions of hyperlipidemia patients in Europe who are underserved by existing options."    

The collaboration expands Menarini's existing cardiology portfolio of 18 products, which address the most widespread cardiometabolic diseases and aim to prevent and reduce risk factors associated with chronic conditions, with the goal of helping patients restore their quality of life.

 "Obicetrapib, if approved, could radically alter the treatment landscape in cardiovascular disease by providing an effective and oral option for hyperlipidemia patients in Europe" said Elcin Barker Ergun, Chief Executive Officer of the Menarini Group. "As a leading company in cardiovascular treatments area, we find it an excellent fit to our portfolio and look forward to collaborating with NewAmsterdam Pharma to advance its development."

Subject to the terms of the agreement, NewAmsterdam will receive an upfront payment of €115 million, as well as €27.5 million in committed R&D funding, for a total of €142.5 million in committed consideration.   NewAmsterdam will be eligible to receive up to €863 million in potential clinical, regulatory and commercial milestones, bringing the total potential deal value to €1,005.5 million. In addition, Menarini will pay NewAmsterdam tiered double-digit percentage royalties from the teens to mid-twenties on net sales of obicetrapib in Europe.

Pursuant to the terms of the agreement, NewAmsterdam will be responsible for further clinical development of obicetrapib and the parties will cooperate in regulatory activities to secure approval for the product.   Menarini will be responsible for all commercialization activities in the licensed territory.

"This alliance exemplifies NewAmsterdam's strategy of engaging with the right partner at the right time with the right deal," said Lina Gugucheva, chief business officer of NewAmsterdam Pharma.   "In addition to Menarini's strong commercial credentials in the cardiovascular field in Europe, this agreement also brings in proceeds that we expect will substantially fund obicetrapib's development through planned Phase 3 data readouts, while allowing NewAmsterdam to retain substantial participation in the potential commercial opportunity in an important major market."

Advisors

Moelis & Company LLC is acting as financial advisor and Covington & Burling LLP is acting as legal advisor to NewAmsterdam Pharma. Goldman Sachs is acting as financial advisor to Menarini.

About Obicetrapib

Obicetrapib is a next-generation oral, low-dose and once-daily CETP inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events. More than 100 million people globally are not achieving LDL-c goals despite the current available standard of care. Obicetrapib was previously tested in ROSE and TULIP[1] randomized double-blind, placebo-controlled Phase 2 trials. Results from the ROSE trial, presented in November 2021 at the AHA Scientific Sessions, included observations that patients on statin therapy who received 5 mg of obicetrapib saw an LDL-c reduction of 42%. Patients who were part of the 10 mg cohort were observed to experience a 51% reduction versus baseline, while the placebo cohort was observed to experience a 7% reduction versus baseline. Both doses were observed to be well tolerated, with no serious adverse effects in the two cohorts and two serious AEs in the placebo arm. Currently, Obicetrapib is being tested in three Phase 3 trials, BROADWAY, BROOKLYN and PREVAIL, and a secondary Phase 2 trial, ROSE2. These studies are intended to examine obicetrapib as a combination therapy as well as its efficacy in adjunct to diet and a maximally tolerated lipid-lowering therapy, and reduction of major adverse cardiovascular events.

About NewAmsterdam Pharma

NewAmsterdam Pharma is a private clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where traditional therapies have been unsuccessful or are not tolerated. NewAmsterdam is investigating obicetrapib, a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-c-lowering therapy for high-risk cardiovascular disease (CVD) patients. Results from NewAmsterdam's ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10mg experienced reduced LDL-c by 51% versus baseline in patients on statin therapy (vs. a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, and closed a $196M (€161M) Series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital. For more information, please visit: www.newamsterdampharma.com.  

About Menarini

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com.  

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; expectations and timing related to the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and the potential approval of NewAmsterdam's therapeutic candidate; the size and growth potential of the markets for NewAmsterdam's therapeutic candidate; the therapeutic and curative potential of NewAmsterdam's therapeutic candidate; and NewAmsterdam's expected cash runway. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of NewAmsterdam's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by anyone as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and many are beyond the control of NewAmsterdam. These forward-looking statements are subject to a number of risks and uncertainties, including uncertainty regarding outcomes of NewAmsterdam's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its therapeutic candidate and other business milestones; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive therapeutic candidates; ability to obtain a sufficient supply of materials; the impact of COVID-19; global economic and political conditions; and the effects of competition on NewAmsterdam's business. If any of these risks materialize or NewAmsterdam's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that NewAmsterdam does not presently know or currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect NewAmsterdam's expectations, plans, or forecasts of future events and views as of the date of this press release. NewAmsterdam anticipates that subsequent events and developments will cause NewAmsterdam's assessments to change. However, while NewAmsterdam may elect to update these forward-looking statements at some point in the future, NewAmsterdam specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing NewAmsterdam's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

[1]  Hovingh, G. K., Kastelein, J. J. P., van Deventer, S. J. H., Round, P., Ford, J., Saleheen, D., Rader, D. J., Brewer, H. B., & Barter, P. J. (2015). Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. In The Lancet (Vol. 386, Issue 9992, pp. 452–460). Elsevier BV. https://doi.org/10.1016/s0140-6736(15)60158-1

Logo- https://mma.prnewswire.com/media/652491/MENARINI_Group_Logo.jpg

More News by PR Newswire India

ViewSonic Kicks off the 2022 ColorPro Award to Capture "Breakthrough" in Photography and Digital Art

Ribbon Announces $52 Million Private Placement Financing Led by Neuberger Berman, JPMorgan Chase & Co., and Swarth Investments Ltd.

New Trading Platform Monsoon Launches to the Public

Media Alert: Supermicro's 3rd Annual Open Storage Summit

Quick Heal joins forces with RevBits to strengthen its cybersecurity portfolio

Tricolour unfurled on the indigenous land rig at MEIL's ICOMM

Cisco Applauded by Frost & Sullivan for Delivering an Integrated Secure Cloud Solution with Its Cisco Umbrella Secure Internet Gateway Packages

Richer People, Poorer Planet: Arçelik calls for greater efficiency at IFA 2022 with the launch of its new cutting-edge technology to enhance sustainable solutions for households

Emeritus Welcomes Higher Ed Leader Mike Malefakis as President of University Partnerships to Expand and Deepen Strategic Partnerships with World-Class Universities

AI Adoption Generates New Business Models and Strengthens Customer Value

BATTERY FIRES WILL NO LONGER MAKE HEADLINES

BAL Pharma Limited announces Q1FY23 results

DCW continues its solid growth momentum in Q1FY23 - its diversified portfolio defends against volatility.

LearnApp.com aims at making 75 schools financially literate on this 75th Independence day

CGTN poll: 78.34% of people believe China vitalized world economy

Healthcare technology company Omics Data Automation, Inc. Announces opening of its Facility in Bangalore, India

FOTON Receives Order for 210 units of iBlue EV Vans in Singapore

Huion Unveils a Innovative Bluetooth Pen Tablet with Dual Dial Controllers: Inspiroy Dial 2

Rockwell Automation Study Finds Traceability, Serialization Key Initiatives in APAC Corporate Supply Chain Strategies

Cantor Fitzgerald confirms the death of President Anshu Jain

Har Ghar Tiranga: NIDF, Chandigarh University create Guinness World Record for largest human image of waving National Flag

Automation Anywhere Collaborates with Planet Water India Foundation to Bring Clean Water to Impoverished Communities Across India

VIRAL FISSION CONCEPTUALISES COLLEGE MEGA FESTIVAL 'COLLIDE'; AIMS TO BRING AN ELEVATED LIVE EVENT EXPERIENCE FOR GEN Z POST-PANDEMIC

Yili Remains the World's Most Valuable Dairy Brand in Brand Finance 2022 Report

Education Cannot Wait Proud to Participate in Global Citizen Festival 2022: Calling on World Leaders and Donors to Empower Girls and End Extreme Poverty Now

Allen Career Institute announces the launch of TALLENTEX 2023; One of the biggest talent search scholarship exams in India

Maple offers 17% off on iPhone 13 this Independence Day

Green Hydrogen & Green Ammonia, Metal & Metal Downstream, and Infrastructure are among the ten industrial projects approved by the HLCA committee of the Government of Odisha

THE GOVERNMENT OF KERALA AND ENTIGRITY EXECUTE MOU TO BOOST EMPLOYMENT & SKILL DEVELOPMENT IN THE STATE

DIIPA KHOSLA'S BEAUTY BRAND, INDÄ’ WILD, SELLS OUT WITHIN 2.5 HOURS OF ITS LAUNCH ON NYKAA

JA Worldwide and JA Africa Announce Partnership with Z Zurich Foundation to Create Bright, Boundless Futures for African Youth

CATL announces its second European battery plant in Hungary

GWM HAVAL DARGO Unveiled in South America, Igniting Passion for Diversified Driving

Rio South Texas: At the Nexus of North American Freight Railways Reports COSTEP

SECUREKLOUD TECHNOLOGIES REPORTS YOY REVENUE GROWTH OF 22.2%; RECURRING REVENUE 42.4% IN Q1 FY23

Azure Power ties up with Siemens Gamesa for Supply of Onshore Wind Turbines

"BUILDING LIVES" Return Visit to Affordable Housing Project in Algeria

The Season 7 XCMG Apprentice wraps up at the headquarter of XCMG

International Youth Day 2022: XCMG Apprentice Season 7 Brings Insights and Opportunities of Construction Machinery Industry

NIDF, Chandigarh University to attempt Guinness World Record

Atal Incubation Centre(AIC) NMIMS Inks MoU with Legalwiz.in

CITYREMOVALIST EXPANDS OPERATIONS, AS SURVEY REVEALS TOP REASONS FOR INCREASE IN RESIDENTS RELOCATING

World's leading wine and spirits exhibition now in Mumbai

ROYAL CANADIAN MINT HONOURS LEGENDARY CANADIAN PIANIST AND JAZZ GIANT OSCAR PETERSON ON NEW $1 CIRCULATION COIN

Intermedia Cloud Communications Wins the Coveted 2022 UC Award for Best UCaaS Solution Provider

Science and Technology Daily: 5G Empowers International Communication Capacity in Multimedia Era

Johnson Controls AI-enhanced OpenBlue Platform Cuts Microsoft's Beijing Campus Energy Footprint

Startek® Wins Silver and Bronze Stevie® Awards in 2022 Stevie Awards for Great Employers

SKYPlay opens pre-registration for Coin Grid prior to the platform's debut

Godrej L'Affaire celebrates #RespectAllBandhans in their touching digital film on the occasion of Raksha Bandhan

Top Organizations Lauded with Prestigious Industry Recognition by Frost & Sullivan for Best-in-Class Performance

Glenmark Pharma reports Revenue of INR 27,773 Mn and PAT of INR 2,111 Mn for Q1 FY 2022-23

Altair Named Official Supplier for Luna Rossa Prada Pirelli Team in its Challenge for the 37th America's Cup

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Webb Fontaine Announces Launch of Niger National Single Window (NNSW) to Bolster Trade

China's economy becomes the world's economic engine: survey

Hisense's Customized Products for the FIFA World Cup 2022™ Global Launch Event, Advancing Technology for Premium Experience

SotaTek: Real-life Use Cases of Blockchain Adoption that Gets your Mindset Right

Knowledge of Design Week 2022 Presents 'Regeneration by Design'

360tf India office expansion to support exporters in growing their business

THE GOLDEN TRAIL SERIES BRINGS THE WORLD'S BEST RUNNERS TO NORWAY

Electric Vehicles Lead the Way for Efficient Battery Solutions Globally

FOTON Secures the Biggest Overseas Order of Electric City Buses from Chile

Viasat Expands Footprint in India, Opens New Office in Hyderabad

Nanoprecise Sci Corp Launches NrgMonitor(TM) to Help Customers Reduce their Emissions & Carbon Footprint

DENTSU RECOGNIZED AS A STRONG PERFORMER IN GLOBAL MARKETING SERVICES REPORT BY INDEPENDENT RESEARCH FIRM

Deltek Announces Speakers and Sponsors for Deltek ProjectCon 2022

Yellow.ai announces the launch of its proprietary DynamicNLP™, a first in the enterprise Conversational AI space

TUMI announced as Official Luggage Partner of Tottenham Hotspur Women's Pre-Season Tour

WITH 40+ NEW INSTALLATIONS, QATAR PRESENTS MORE THAN 100 MAJOR WORKS OF PUBLIC ART AHEAD OF THE FIFA WORLD CUP QATAR 2022™

NuraLogix researchers announce AI models that can predict Metabolic Risks

A TROPICAL ESCAPE WITH ULTIMATE EXPERIENCES AT THE RITZ-CARLTON, BALI

CU UCRD's bio-insecticide to revolutionise India's fruit production

No-Code DevOps platform Humalect raises $ 750k in seed round led by StartupXseed Ventures

ONE Advertising - the creative force behind Divya Bhaskar's Sachi Vaat Bedhadak campaign

Sennheiser announced exciting deals on its best-selling products during the Amazon Great Freedom Festival Sale 2022

YES BANK and IBSFINtech tie up to provide enhanced digital services for corporate clients

Multi-Blockchain Wallet App Nufinetes Releases New Feature to View NFTs on Ethereum and VeChain

impress.ai and Aon to help employers improve hiring accuracy, streamlining the end-to-end recruitment process

Shivalik Bimetal posts solid Q1FY23 top and bottom lines YoY, on the back of resurging global demand

Edvoy CEO, Sadiq Basha, named Visionary Entrepreneur of the Year 2022 by WPI

Indo Amines Limited declares tremendous growth, Operational Revenue up by 46%

Over 550,000 people set to attend the International Saudi Falcons and Hunting Exhibition in Malham, Riyadh

HPL Electric and Power Ltd reports solid Q1FY23 Results

Spinny's Take on the Swiftly Changing Automobile Industry

World's Largest Fintech Conference is Back

15th Singapore International Energy Week (SIEW) Registration Now Open

Indian WWW Treatment Market to Experience a Boom as the Country witnesses increase in Private Investments

Khadim India records 190% growth in Retail Sales in Q1 FY 23

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Adda52 announces 'Freedom Fest' - an online Poker tournament to celebrate 75 years of Independence

Online Proctoring Solution Provider Shinkan Launches Shinkan Edge To Revolutionise Corporate Recruitment

The 49th CIFF Guangzhou Presents the Entire Furniture Supply Chain to 50 Million Visitors Online and Offline

Xinhua Silk Road: N.China's Lingqiu County takes organic agriculture as effective way to promote rural development

EARTHDAY.ORG'S THE CANOPY PROJECT ANNOUNCES MANGROVE PLANTING PROJECT IN BANGLADESH WITH CRYSTAL INTERNATIONAL GROUP LIMITED

Here and Now, There and Then: Prince Mohammad Bin Fahd University Drives Innovation and Invention, Locally and Globally

Global supply chain reconfiguration to persist through 2030

Hakuhodo and DAC launch H+, a strategic group to "Empower Your Digital Future" with one of APAC's most distinctively audience-centric data marketing approaches

ONESIGHT ESSILORLUXOTTICA FOUNDATION ANNOUNCES PUBLICATION OF NEW ARTICLE

Recorded Future Launches National Cyber Defense Intelligence Kit

Launched to immediate global acclaim via Livestream: Absen's pioneering KLCOB Micro LED product series

SEMI Applauds President Biden's Signing of CHIPS and Science Act of 2022

Anthony Di Iorio Opens Whitelist for New Global Project to Empower a User-Controlled Internet; Project to Be Unveiled November 3

New measures agreed to strengthen the partnership between Mongolia and China

Focused Photonics Inc. Selects Wolters Kluwer CCH® Tagetik Expert Solution for its Disclosure Management Needs

Snapmaker Announces Artisan 3-in-1 3D Printer is Available for Pre-order Today

Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth

DevOps Institute Releases First Ever 'Global SRE Pulse 2022' Report

WorkForce Software Honored Alongside IBM and Google in Comparably's Annual Ranking of Top Companies for Having the Best Leadership Team

Aon appoints James Platt as Chief Digital Officer and Mindy Simon joins the firm as Chief Operating Officer

Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

Satellite Software Innovator Antaris Announces Close of $4.2 Million Seed Funding Round to Accelerate Development of Software Solutions for Space

GOLDIAM reports its Q1FY23 results, share of Lab grown diamond & jewellery strengthens further

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

Nobu Hospitality Expands its Footprint in Asia Pacific

Gunzilla Games Raises $46M to Redefine the Battle Royale Genre By Letting Players Trade Their In-Game Items in "Off The Grid"

Deepak Nitrite Demonstrates Strong Topline Performance with 35% Y-o-Y Growth

A leading ERP company, Focus Softnet eyes revenues of 160 crores, projects a growth of about 20% Y-O-Y

Quest Global Becomes Arm Approved Design Partner

GCLSI Receives French Carbon Footprint Certification for Its 182 and 210 Series of Photovoltaic Modules

Triumph International India launches their first exclusive retail store in Pune

Indian Ice-Cream Manufacturers' Association (IICMA) met with Finance Minister Nirmala Sitharaman to discuss GST rates on supply of ice cream by ice cream parlours in India

Dyninno opens new office in Cyber City; Plans more offices in Gurugram and Mumbai

Woxsen University bestows Chair Professorships in honour of International Experts

People Matters TechHR 2022 Brings Fresh Eyes to the World of HR

PACORR Launches Melt Flow Index Tester - Fully Automatic Version

RateGain Launches Airline Travelers' Forecast to Help Commercial Teams Drive Higher ROI

Thai Digital Content Gaining Increasing Recognition Around the World

Crave InfoTech launches White Paper on Top Supply Chain Challenges

GRL accelerates the authorization of biometrics devices for Government of India projects

Everest Group Names Automation Anywhere a Leader in the inaugural Task Mining PEAK Matrix® Assessment 2022

China Wuling's First Global Electric Vehicle Air ev Rollouted, First Step In Indonesia

FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID

GIGABYTE Releases 600 series BIOS updates ready for Intel's upcoming new-gen processors

Soroco Named a Leader in Everest Group's PEAK Matrix® for Task Mining Technology Provider 2022

Starburst Celebrates 10th Anniversary of Trino

Point-of-Care Ultrasound Certification Academy to Host World Conference

The "Picturesque and Dynamic Zhejiang" Global Short Video Competition Launches

BlackBerry Commended by Frost & Sullivan for Optimizing Edge-to-cloud Performance, Security, Privacy, and Scalability with its IVY Platform for Automakers

Amwell Applauded by Frost & Sullivan for its Comprehensive Digital Care Delivery Enablement Platform, Converge™

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Axis Bank in partnership with CRMNEXT wins the Best CRM Implementation Award by Asian Banker

Godrej Properties Ltd. unveils insights from Home Livability Factors research

Gear Up with All New Helix Metalfit 3.0 Smartwatch Launched by Timex Group India

Roundtable with Leading Doctors and Youth Aims for a Tobacco-Free Future for India

Catalytic Investment to Improve Community Health Care for Millions Across Africa

DIFC Launches First Global Family Business and Private Wealth Centre

2022 ITOE - Home Lifestyle Expo Opens, Provides Strong Impetus for Development of Digital Trade

FRIMLINE LAUNCHES INDIA'S 1st ORAL CARE RANGE FOR PREGNANT WOMEN

Aptus Value Housing Finance India Limited announces Q1 FY23 Results

Tata Communications enhances InstaCC™ Platform with digital features

/C O R R E C T I O N -- Lentra/

Leading Solar Energy Solution Provider Haitai Solar Launches IPO on Beijing Stock Exchange

Kiko Live to be launched on ONDC in September

Clarivate Selected by Singapore's National Library Board to Play a Part in Building Libraries of the Future

TCL Reaffirms its Leadership in Mini LED TVs in 2022

NID Foundation unveils Heartfelt-The Legacy of Faith; A book showcasing PM Modi's relationship with the Sikh community at Melbourne

AirCarbon Exchange Offsets Emissions Through to December 2023

Celebrate independence from the worries of interest rates with Tata Housing Development Company's 'Its Interesting' campaign with 3.50% interest rate for 12 months in the 75th year of Independence

Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development

M/V Riva Wind and M/V Arizona Both Sail from Ukraine with 105,000 Tons of Grain

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Thousands witness iconic Attari-Wagah bo...
Rahul Gandhi refuses to comment on PM Mo...
President Murmu extends greetings to cit...
Two die of electrocution while hoisting ...
Human activities altered even most resil...
4 dead including retired SP as truck ram...
More...    
 
 Top Stories
China's semiconductor output dips 1... 
Domestic help tied, stripped naked ... 
Remote Pilot certificates witness r... 
Iran categorically denies any link ... 
Punjab Police recovers weapons used... 
Maharaja Trophy: All-round efforts ... 
Delhi: Habitual thief involved in 4... 
There is no dearth of talented badm...